Raily Aesthetic Medicine International Holdings Limited Provided consolidated unaudited earnings guidance for the year ended 31 December 2022. For the period, the Board expects the Group to record a revenue of approximately RMB 165 million (2021: revenue of approximately RMB 188 million) and expects to record a loss attributable to owners of the parent of approximately RMB 16 million (2021: loss of approximately RMB18 million).